Remove 2029 Remove Communication Remove Insurance Coverage and Processing
article thumbnail

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!

article thumbnail

CHMP rejects Elevidys in latest setback for Sarepta

Pharmaceutical Technology

According to GlobalData, the CGT market was estimated to be $5.88bn in 2023 and is projected to reach $80bn by 2029. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications.